RxDoctor Payments Data

David Armenia, MD

Cardiovascular Disease · Schenectady, NYNPI 1023060621

Payments from drug & device makers

$855in general payments, 2019–2025

Across 34 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$344
  • Edwards Lifesciences$185
  • Abbott$86
  • Boehringer Ingelheim$61
  • Pfizer$44
  • Amgen$35
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$84298%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$855 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$87,529
Medicare patients
407
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban661$766,441
XareltoRivaroxaban114$115,071
Repatha SureclickEvolocumab45$39,450
EntrestoSacubitril/Valsartan28$39,257
Praluent PenAlirocumab28$22,084
JardianceEmpagliflozin16$13,241
FarxigaDapagliflozin Propanediol14$9,937
Atorvastatin Calcium732$9,098
Metoprolol Succinate671$8,473
Ezetimibe150$5,830
Rosuvastatin Calcium246$5,552
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,556
Torsemide184$3,126
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$2,983
Amlodipine Besylate455$2,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$766,441661 claims
Johnson & JohnsonXarelto$19$115,071114 claims
NovartisEntresto$344$39,25728 claims
Boehringer IngelheimJardiance$61$13,24116 claims
AstraZenecaFarxiga$14$9,93714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →